| Trial | Treatments | Patients | Method |
|---|
| Taskinen | linagliptin 5 mg once daily (n=524) vs. placebo add on MET (n=177) | patients with inadequately controlled type 2 diabetes for whom metformin therapy is inappropriate due to intolerability or contraindication | Sample size: 524/177 Primary endpoint: FU duration: |
| Lewin, 2010 | linagliptin 5 mg
(n=-9) vs. placebo (add-on to sulphonylurea)
(n=-9)
| patients with type 2 diabetes and insufficient glycaemic control
| double-blind Sample size: -9/-9 Primary endpoint: change from baseline HbA1c FU duration: 18 weeks
|
| Owens | linagliptin
(n=-9) vs. combination of metformin and an SU
(n=-9)
| type 2 diabetes mellitus with insufficient glycaemic control with metformin in combination with a sulphonylurea
| Sample size: -9/-9 Primary endpoint: change from baseline in HbA1c FU duration: 24 weeks
|
| Del Prato | Linagliptin monotherapy
(n=-9) vs. placebo
(n=-9)
| Type 2 Diabetic Patients With Insufficient Glycemic Control
| double-blind Sample size: -9/-9 Primary endpoint: change from baseline in HbA1c FU duration: 24 weeks
|
| CAROLINA, 2012 | linagliptin (n=776) vs. glimepiride 1-4 mg QD (n=775) | patients with type 2 diabetes at elevated cardiovascular risk receiving usual care | double-blind Sample size: 776/775 Primary endpoint: change in HbA1c FU duration: 2 years |
| Gallwitz, 2012 | linagliptin (5 mg once daily) add-on therapy to preferably > 1500 mg metformin (n=777) vs. glimepiride (1—4 mg) orally once daily add-on therapy to preferably > 1500 mg metformin (n=775) | type 2 diabetes mellitus with insufficient glycaemic control with metformin | double-blind Parallel groups Sample size: 777/775 Primary endpoint: change from baseline in HbA1c FU duration: 104 weeks |
| Gomis, 2011 | initial combination of 30 mg pioglitazone plus 5 mg linagliptin (n=-9) vs. pioglitazone plus placebo (n=-9) | patients with inadequately controlled type 2 diabetes | Sample size: -9/-9 Primary endpoint: FU duration: 24 weeks |
| Forst, 2010 | Linagliptin (1, 5, or 10 mg taken once daily)
(n=-9) vs. placebo (on top Metformin )
(n=-9)
| patients with type 2 diabetes mellitus who are not at goal with their HbA1c levels
| double-blind Sample size: -9/-9 Primary endpoint: FU duration: 12 weeks
|
